在国内,靶向抗癌药几乎等同于“昂贵的国外专利药”。然而中国工程院院士、中国医学科学院肿瘤医院孙燕教授9月17日公布的消息有望改变这一现实:我国具有完全自主知识产权的小分子靶向抗癌创新药盐酸埃克替尼完成三期临床试验,疗效得到证实。盐酸埃克替尼是以表皮生长因子受体激酶为靶标的新一代靶向抗癌药,完全由我国科学工作者和肿瘤临床专家自主原创,经历8年时间研 In China, targeted anticancer drugs are almost equivalent to “expensive foreign patent medicine.” However, the Chinese Academy of Engineering, Cancer Hospital, Chinese Academy of Medical Sciences Professor Sun Yan September 17 announcement of the message is expected to change the reality: China has completely independent intellectual property rights of small-molecule targeted anticancer drug icritini hydrochloride to complete Phase III clinical Test, efficacy confirmed. Icitinib hydrochloride is a new generation of targeted anti-cancer drugs targeting epidermal growth factor receptor kinase. It is entirely original by our scientists and clinical oncologists and has undergone 8 years of research